Longbow Research Begins Coverage on Tempus AI (NASDAQ:TEM)

Longbow Research began coverage on shares of Tempus AI (NASDAQ:TEM) in a research note published on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $48.00 price target on the stock.

A number of other brokerages also recently weighed in on TEM. Loop Capital initiated coverage on shares of Tempus AI in a research note on Tuesday. They issued a buy rating and a $48.00 target price for the company. JPMorgan Chase & Co. assumed coverage on Tempus AI in a report on Tuesday. They set an overweight rating and a $42.00 price objective on the stock. TD Cowen started coverage on Tempus AI in a research report on Tuesday. They issued a buy rating and a $50.00 price objective on the stock. Morgan Stanley assumed coverage on Tempus AI in a research report on Tuesday. They set an overweight rating and a $44.00 target price for the company. Finally, Needham & Company LLC started coverage on Tempus AI in a report on Tuesday. They issued a buy rating and a $47.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tempus AI currently has a consensus rating of Buy and a consensus price target of $45.63.

Tempus AI Stock Up 7.1 %

Tempus AI stock opened at $37.50 on Tuesday. Tempus AI has a 12-month low of $22.89 and a 12-month high of $43.88.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.